Physician profile
Sally Primus
NPI 1114292208
$3,972.98
in general payments reported to CMS, 2019-2025
26 companies · $709 in 2025
The $709 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $209 · 2021: $358 · 2022: $430 · 2023: $833 · 2024: $736 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $913.44 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Regeneron Healthcare Solutions, INC. | $737.41 | 2019-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $479.09 | 2019-2021 | |
| Shire North American Group INC | $212.50 | 2019 | |
| Oyster Point Pharma, INC. | $188.00 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $161.00 | 2019-2025 | Cequa |
| Genentech USA, INC. | $150.65 | 2023-2024 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $130.35 | 2020-2023 | |
| Amgen INC. | $116.85 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.08 | 2019-2021 | |
| Abbvie INC. | $108.37 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $96.22 | 2024 | Purified Cortrophin Gel |
| Regeneron Pharmaceuticals, INC. | $75.00 | 2023 | Eylea |
| Tarsus Pharmaceuticals, INC. | $72.45 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $54.43 | 2021-2024 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $49.81 | 2020-2021 | |
| Horizon Therapeutics Plc | $44.85 | 2023 | Tepezza |
| Alcon Vision LLC | $42.75 | 2022-2025 | Eysuvis |
| Kala Pharmaceuticals, INC. | $42.56 | 2019 | |
| Vanda Pharmaceuticals INC. | $40.43 | 2019 | |
| Biotissue Holdings INC. | $37.34 | 2019-2025 | |
| Astellas Pharma US INC | $31.77 | 2024 | Izervay |
| Coopervision INC. | $27.27 | 2023 | Myday Contact Lens |
| Harrow Eye, LLC | $20.80 | 2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $14.46 | 2023 | Acuvue |
| New World Medical,INC. | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Primus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.